WebSite > HitGen Inc.

HitGen Inc.

  • Company Name HitGen Inc.
  • Tel 028-85197385
  • Email jz.yang@hitgen.com
  • WebSite www.hitgen.com/
  • CB Index 58
  •       HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for oligonucleotide-based therapeutics (OBT), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage. For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com. For media inquiries: media@hitgen.com For investor inquiries: investors@hitgen.com For business development: bd@hitgen.com
HitGen Inc. Product List
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Product Name 
  • MF C48H56N5O10P
  • CAS 1120329-56-7
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Product Name pAmpG
  • MF C27H43N11O14P2
  • CAS 2638447-50-2
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •